A citation-based method for searching scientific literature

Gregory Aubert, Ola J Martin, Julie L Horton, Ling Lai, Rick B Vega, Teresa C Leone, Timothy Koves, Stephen J Gardell, Marcus Krüger, Charles L Hoppel, E Douglas Lewandowski, Peter A Crawford, Deborah M Muoio, Daniel P Kelly. Circulation 2016
Times Cited: 277







List of co-cited articles
1184 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure.
Kenneth C Bedi, Nathaniel W Snyder, Jeffrey Brandimarto, Moez Aziz, Clementina Mesaros, Andrew J Worth, Linda L Wang, Ali Javaheri, Ian A Blair, Kenneth B Margulies,[...]. Circulation 2016
219
51

The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense.
Julie L Horton, Michael T Davidson, Clara Kurishima, Rick B Vega, Jeffery C Powers, Timothy R Matsuura, Christopher Petucci, E Douglas Lewandowski, Peter A Crawford, Deborah M Muoio,[...]. JCI Insight 2019
70
48

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
31

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
488
28

Myocardial fatty acid metabolism in health and disease.
Gary D Lopaschuk, John R Ussher, Clifford D L Folmes, Jagdip S Jaswal, William C Stanley. Physiol Rev 2010
25

Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.
Kim L Ho, Liyan Zhang, Cory Wagg, Rami Al Batran, Keshav Gopal, Jody Levasseur, Teresa Leone, Jason R B Dyck, John R Ussher, Deborah M Muoio,[...]. Cardiovasc Res 2019
49
51

Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients.
Roni Nielsen, Niels Møller, Lars C Gormsen, Lars Poulsen Tolbod, Nils Henrik Hansson, Jens Sorensen, Hendrik Johannes Harms, Jørgen Frøkiær, Hans Eiskjaer, Nichlas Riise Jespersen,[...]. Circulation 2019
81
29



Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
21

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
21

Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling.
Rebecca C Schugar, Ashley R Moll, D André d'Avignon, Carla J Weinheimer, Attila Kovacs, Peter A Crawford. Mol Metab 2014
84
23

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
125
19

The failing heart--an engine out of fuel.
Stefan Neubauer. N Engl J Med 2007
18

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
17

Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.
Tadahiro Shimazu, Matthew D Hirschey, John Newman, Wenjuan He, Kotaro Shirakawa, Natacha Le Moan, Carrie A Grueter, Hyungwook Lim, Laura R Saunders, Robert D Stevens,[...]. Science 2013
715
17

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Carlos G Santos-Gallego, Juan Antonio Requena-Ibanez, Rodolfo San Antonio, Kiyotake Ishikawa, Shin Watanabe, Belen Picatoste, Eduardo Flores, Alvaro Garcia-Ropero, Javier Sanz, Roger J Hajjar,[...]. J Am Coll Cardiol 2019
139
17

Ketone body metabolism and cardiovascular disease.
David G Cotter, Rebecca C Schugar, Peter A Crawford. Am J Physiol Heart Circ Physiol 2013
187
16


Loss of Metabolic Flexibility in the Failing Heart.
Qutuba G Karwi, Golam M Uddin, Kim L Ho, Gary D Lopaschuk. Front Cardiovasc Med 2018
98
15

Increased Cardiac Uptake of Ketone Bodies and Free Fatty Acids in Human Heart Failure and Hypertrophic Left Ventricular Remodeling.
Gabor Voros, Joris Ector, Christophe Garweg, Walter Droogne, Johan Van Cleemput, Nele Peersman, Pieter Vermeersch, Stefan Janssens. Circ Heart Fail 2018
37
40

Myocardial substrate metabolism in the normal and failing heart.
William C Stanley, Fabio A Recchia, Gary D Lopaschuk. Physiol Rev 2005
14

Cardiac-Specific Bdh1 Overexpression Ameliorates Oxidative Stress and Cardiac Remodeling in Pressure Overload-Induced Heart Failure.
Motoki Uchihashi, Atsushi Hoshino, Yoshifumi Okawa, Makoto Ariyoshi, Satoshi Kaimoto, Shuhei Tateishi, Kazunori Ono, Ryoetsu Yamanaka, Daichi Hato, Yohei Fushimura,[...]. Circ Heart Fail 2017
42
33

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
916
13

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
259
13

Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
177
13

Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Salva R Yurista, Herman H W Silljé, Silke U Oberdorf-Maass, Elisabeth-Maria Schouten, Mario G Pavez Giani, Jan-Luuk Hillebrands, Harry van Goor, Dirk J van Veldhuisen, Rudolf A de Boer, B Daan Westenbrink. Eur J Heart Fail 2019
83
15

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.
Yun-Hee Youm, Kim Y Nguyen, Ryan W Grant, Emily L Goldberg, Monica Bodogai, Dongin Kim, Dominic D'Agostino, Noah Planavsky, Christopher Lupfer, Thirumala D Kanneganti,[...]. Nat Med 2015
682
13

Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.
M N Sack, T A Rader, S Park, J Bastin, S A McCune, D P Kelly. Circulation 1996
476
13

Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes.
Pete J Cox, Tom Kirk, Tom Ashmore, Kristof Willerton, Rhys Evans, Alan Smith, Andrew J Murray, Brianna Stubbs, James West, Stewart W McLure,[...]. Cell Metab 2016
182
13

Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure.
Haipeng Sun, Kristine C Olson, Chen Gao, Domenick A Prosdocimo, Meiyi Zhou, Zhihua Wang, Darwin Jeyaraj, Ji-Youn Youn, Shuxun Ren, Yunxia Liu,[...]. Circulation 2016
182
12

Mitochondrial protein hyperacetylation in the failing heart.
Julie L Horton, Ola J Martin, Ling Lai, Nicholas M Riley, Alicia L Richards, Rick B Vega, Teresa C Leone, David J Pagliarini, Deborah M Muoio, Kenneth C Bedi,[...]. JCI Insight 2016
87
13

Blood ketone bodies in congestive heart failure.
J Lommi, M Kupari, P Koskinen, H Näveri, H Leinonen, K Pulkki, M Härkönen. J Am Coll Cardiol 1996
118
12

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
291
11

β-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes.
Manabu Nagao, Ryuji Toh, Yasuhiro Irino, Takeshige Mori, Hideto Nakajima, Tetsuya Hara, Tomoyuki Honjo, Seimi Satomi-Kobayashi, Toshiro Shinke, Hidekazu Tanaka,[...]. Biochem Biophys Res Commun 2016
41
26

The diabetic heart utilizes ketone bodies as an energy source.
Yuji Mizuno, Eisaku Harada, Hitoshi Nakagawa, Yoshinobu Morikawa, Makoto Shono, Fumihito Kugimiya, Michihiro Yoshimura, Hirofumi Yasue. Metabolism 2017
56
19

Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy.
Víctor G Dávila-Román, Giridhar Vedala, Pilar Herrero, Lisa de las Fuentes, Joseph G Rogers, Daniel P Kelly, Robert J Gropler. J Am Coll Cardiol 2002
320
11

Ketone Body Infusion With 3-Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study.
Lars C Gormsen, Mads Svart, Henrik Holm Thomsen, Esben Søndergaard, Mikkel H Vendelbo, Nana Christensen, Lars Poulsen Tolbod, Hendrik Johannes Harms, Roni Nielsen, Henrik Wiggers,[...]. J Am Heart Assoc 2017
62
17

Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy.
Liyan Zhang, Jagdip S Jaswal, John R Ussher, Sowndramalingam Sankaralingam, Cory Wagg, Michael Zaugg, Gary D Lopaschuk. Circ Heart Fail 2013
123
10


Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
190
10

Comprehensive quantification of fuel use by the failing and nonfailing human heart.
Danielle Murashige, Cholsoon Jang, Michael Neinast, Jonathan J Edwards, Alexis Cowan, Matthew C Hyman, Joshua D Rabinowitz, David S Frankel, Zolt Arany. Science 2020
43
23

Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment.
Anna E Wentz, D André d'Avignon, Mary L Weber, David G Cotter, Jason M Doherty, Robnet Kerns, Rakesh Nagarajan, Naveen Reddy, Nandakumar Sambandam, Peter A Crawford. J Biol Chem 2010
67
13

Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure.
Takao Kato, Shinichiro Niizuma, Yasutaka Inuzuka, Tsuneaki Kawashima, Junji Okuda, Yodo Tamaki, Yoshitaka Iwanaga, Michiko Narazaki, Tetsuya Matsuda, Tomoyoshi Soga,[...]. Circ Heart Fail 2010
167
9

Insulin Signaling and Heart Failure.
Christian Riehle, E Dale Abel. Circ Res 2016
158
9

Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.
Heinrich Taegtmeyer, Martin E Young, Gary D Lopaschuk, E Dale Abel, Henri Brunengraber, Victor Darley-Usmar, Christine Des Rosiers, Robert Gerszten, Jan F Glatz, Julian L Griffin,[...]. Circ Res 2016
112
9


Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
245
9

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.
Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li,[...]. Cardiovasc Diabetol 2019
106
9

beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content.
William C Stanley, Steven R Meadows, Krista M Kivilo, Bridgette A Roth, Gary D Lopaschuk. Am J Physiol Heart Circ Physiol 2003
52
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.